San Francisco / California / United States
HepaLife Technologies is engaged in the development of a cell-based bioartificial liver system under the HepaMate brand name, which is used to treat patients with severe liver failure. The company has also published more than 50 scientific papers on bioartificial liver system technology. HepaLife Technologies liver system is designed to combine blood detoxification with liver cell therapy to provide whole liver functioning in patients with severe forms of liver failure. Its liver system reduces the risk of pre-transplant death in fulminant hepatic failure patients.
